Resistance to multiple chemotherapeutic agents has been related t o the production of P-glycoprotein, a trans-membrane drug efflux pump that is encoded by the multidrug resistance (MDR) gene mdrl. To investigate whether mdrl could be involved in clinical resistance t o chemotherapy in acute leukemias, we have analyzed retrospectively the RNA from adult acute leukemia cells by slot-blot hybridization with a human mdrl probe. Units of mdrl expression were defined by reference t o drug-sensitive human sarcoma and K562 leukemia cell lines (1 U) and the highly resistant doxorubicin selected leukemia cells K562/R7 (50 U). We studied 41 adult patients with acute leukemias: 5 acute lymphoblastic leukemias, 23 acute myeloid leukemias, and 13 secondary leukemias or blast crisis of chronic myelogenous leukemia. Expression of 10 U or more of mdrl was found in 6 of 31 (19Y0) leukemias at diagnosis, versus 5 of 10 ESPITE SOME SUCCESS in childhood acute lympho-D blastic leukemia, the long-term prognosis of acute leukemia is still poor. Biochemical drug resistance present from the outset in leukemic cells or arising by somatic mutation is thought to be the major cause for failure of chemotherapy in these cancers.'
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A mechanism of resistance termed multidrug resistance (MDR) has been described in many cancer cell lines exposed to anthracyclines, vinca alkaloids, podophyllotoxins, and other agents."' MDR is related to the production of P-glycoprotein (P-gp), a 170-Kd glycoprotein that functions as a trans-membrane drug efflux pump and is encoded by the multidrug resistance gene mdrl.'6 Cells expressing this protein exhibit reduced accumulation of different drugs,' including many agents important in the treatment of acute leukemias such as the anthracyclines, vincristine (Vcr), amsacrine (AMSA), mitoxantrone (Mit), and etoposide (VP16).
High expression of the mdrl gene has been reported in several human cancers, including carcinomas of the colon, pheochrom~cytoma,~~~ renal cancer," sarcomas," and advanced ovarian cancer." Initial reports in patients with multiple myeloma and leukemias have found low mdrl expression in most patients at diagno~is.~~~~''~'~ If high mdrl expression correlates with a poor response to therapy, the prospective identification of such patients could lead to therapeutic strategies to circumvent or overcome MDR. These strategies might include the more intensive use of chemotherapeutic agents not involved in the MDR phenotype, or modulation of MDR by inhibitors of P-gp such as erap pa mil,'^^^" cyclosporine, 21 or others.2Z In the current study, we correlate mdrl expression in adult acute leukemias with both treatment outcome and in vitro sensitivity of leukemic clonogenic cells.
PATIENTS AND METHODS
Patients. Forty-five specimens were studied from 41 patients with adult acute leukemias ( Table 1 ). The average age was 45 years (range 15 to 82 years). The average peripheral white blood cell (WBC) count was 115 x 109/L (SD, 2 156 x lO'/L), with 82 x 109/L (SD, 2 119 x 109/L) circulating leukemic cells. The mean percent of leukemic cells in the bone marrow was 72% (SD, *18%).
There were 13 cases of secondary leukemia (10 after myeloproliferative syndrome, 3 after refractory anemia with an excess of blasts). Among these, 2 were lymphoblastic (CALLA+), and 11 were myeloid. The 28 patients with primary leukemias included 5 lymphoblastic (2 CALL, 1 T-ALL, 1 Burkitt's, and 1 lymphosarcoma cell leukemia), and 23 myeloid leukemias (3 M1,6 M2,l M3, 8 M4, and 5 M5 according to the French-American-British [ F B I classification).
Specimens were obtained from 31 patients at diagnosis and 10 patients after therapy, which included MDR-related drugs (four in first phase with resistant disease, four in first relapse, two in second relapse). A total of 36 patients received chemotherapy, which included MDR-related drugs and is detailed in Table 1 . Treatment for the seven patients with ALL included either Vcr or vindesine (Vind) with prednisone (Pdn) and the addition of doxorubicin (Adr, three patients) or AMSA (two patients). Therapy for acute myeloid leukemia (AML) included 24 patients treated with daunorubicin (Dnr) and cytosine arabinosine (araC) according to the AML-8 protocol of the E.O.R.T.C., four relapsed AML patients treated with AMSA and high-dose araC, and one with Dnr, Vcr, and Mit.
Fifteen patients obtained a complete remission (CR), according patients who failed to achieve CR, five died during therapeutic aplasia and are classified as E4 failure according to Preisler,x and 16 were primarily resistant to therapy (13 partial resistance or E2 and three absolute resistance or El). Mononuclear cells from bone marrow aspirates or peripheral blood were separated by Ficoll-Hypaque density gradient centrifugation and stored at -80°C. Total cellular RNA was prepared according to the acid guanidinium phenol chloroform technique.= Aliquots of 2.5,5, and 10 pg of total cellular RNA were dissolved in 100 p L water, 300 p L of a solution of 6.15 molL formaldehyde and 1OX SSC were added and incubated for 15 minutes at 65T, and then loaded onto a Zeta-probe nylon blotting membrane (Bio-Rad Laboratories, Richmond, CA) using a slot-blot apparatus (Schleicher and Schuell, Keene, NH). Membranes were heated for 2 hours at 80°C in a vacuum oven and then prehybridized for 30 minutes at 65°C with a hybridization solution containing 1% bovine serum albumin (BSA), 1 mmolL EDTA, 7% sodium dodecyl sulfate (SDS), 0.5 molL NaH, PO,, pH 7.2.% A 1.2-kb, 5' mdrl cDNA4 was radiolabeled with [3ZP]-deoxycytidine triphosphate by the random priming technique?' This region of mdrl is only 50% to 60% homologous to the other member of the human mdr gene family, mdr2 (also called ~t d r 3 ) .~ It does not include the highly homologous nucleotide binding consensus sequences of mdr genes, and therefore should not cross-hybridize with mdr2 under high-stringency conditions.
Membranes were hybridized overnight at 65°C by adding radiolabeled probe at an activity of 1 x lo6 cpm/mL to the hybridization solution and then washed 4 x 30 minutes at 65°C. Autoradiograms were exposed for 1 to 4 days at -80°C and then analyzed with an UltroScan X L laser densitometer and GelScan XL software (Pharmacia LKB Biotechnology Inc, Piscataway, NJ).
The mdrl probe was removed by boiling for 30 minutes in 1 m m o w EDTA and 1% SDS. Variability of RNA loading was corrected by reprobing with a [3ZP]-deoxycytidine triphosphatelabeled cDNA probe for a Xenopus ribosomal gene that crosshybridizes with human ribosomal RNA.29 RNAs from cell lines were included on each blot as negative and positive controls.
RNA slot-blot analysis of mdrl eupression.
The ratio of the signals for mdrl and ribosomal RNA was calculated using the area under the curve determined by densitometry. The negative control was MES-SA, a drug-sensitive uterine sarcoma lineM with very low expression of the mdrl gene (defined as 1 U of expression). The positive control was K562/R7, a resistant leukemic cell line" that was 75-fold resistant to Adr compared to the parental cell line, K562, with a relative increase ofmdrl mRNA of 50 U. Sample values were expressed as units of expression relative to MES-SA and K562/R7 cells. All the samples were tested at least twice on two different blots with two different batches of probe. The correlation coefficient for separate determination of mdrl expression by slot blotting was 0.927.
Because of concerns regarding the use of degraded RNA from clinical leukemia specimens, we performed an RNAse digestion experiment using intact RNA from an MDR cell line derived from MES-SA cells. RNA was incubated with 0.01, 0.1, and 1.0 ngimL of RNAse for 15 minutes, and 0.3, 1.0, and 3.3 pg of the RNA were applied to the slot-blotting apparatus in triplicate and hybridized with the mdrl probe. As expected, progressive degradation of the RNA was evident on ethidium bromide staining after agarose gel electrophoresis. However, degradation of the RNA did not lead to a falsely high or low hybridization signal for the mdrl gene in this experiment.
Data for in vitro drug sensitivities are available for only 22 of the 41 specimens because some samples were frozen directly for molecular studies only, and 10% of the samples that were plated did not grow sufficiently under our assay conditions.
The technique of blast colony formation has been described previously.'* Briefly, 2 x lo4 T-depleted cells in 0.1 mL of (Y medium were plated in methyl cellulose (0.8%), 20% fetal calf serum (FCS; Flow Laboratories), and 10% phytohemagglutininleukocyte conditioned medium in 1-mL microwells (Titertek Laboratories). Eight to 10 microwells were plated for each drug exposure and incubated in a moist atmosphere with 6% carbon dioxide. Before plating, the cells were incubated in ( were washed and plated as before. For combined Dnr/araC sensitivity, cells were exposed to IO-' m o l n araC in the culture medium after exposure to Dnr. Aggregates of greater than 20 cells were counted at day 7 in at least four wells. The percentage inhibition of CFU-L was calculated by comparison with growth of control plates without drug exposure. Resistance was defined as less than 70% CFU-L inhibition after Dnr, AMSA, or VP16 exposure, and less than 80% inhibition after Dnr/araC or Mit exposure."
Linear correlation was used to test for the reproducibility of blotting and sample values relative to positive and negative controls. Fisher's exact test was used to test for significant differences between groups. I n the analysis, the anthracyclines Dnr and Adr, AMSA. Mit, VP16, Vcr, and Vind were considered to be MDR-related drugs, whereas cyclophosphamide, araC, and Pdn were not considered to be involved in the M D R phenotype.
Sruristical anuly5is.
RESULTS
Figure 1 depicts a representative RNA slot blot hybridized with the 5'-mdrl (upper row) and ribosomal (lower row) cDNA probes. The levels of mdrl mRNA expression of the 41 patients, divided according to no prior versus prior therapy, are shown in Table 2 . The results of slot blotting were very reproducible from blot to blot (3 = .93) and were consistent when normalized to either of the control cell lines, MES-SA or K56UR7 (3 = .91). Absent or low levels of mdrl expression, 0 to 1 U, were graded as (-) and observed in 13 (32%) patients, and moderate elevation of 2 to 4 U (+/-) was seen in 10 (24%). Levels between 5 and 9 U (+) were seen in seven patients (17%), and expression of in Fig 1 appears to have a slight positive signal, two other blots of this specimen were negative and it is graded as negative.
High expression of 2 10 U of mdrl (+ +) was found in 50% of patients previously treated with MDR-related drugs, compared with 19% of untreated patients (P = .06).
No significant difference in expression was seen between primary and secondary leukemias. No correlations were found between mdrl expression and the number of circulating leukemic cells, the percentage of bone marrow blasts, the FAB classification, or the age of the patients. Serial determinations of mdrl expression in the four cases tested before and after treatment showed an increased expression in two patients ( Table 3) . One patient remained negative for mdrl expression after failure of chemotherapy, and one patient with high expression after Dnr/araC therapy exhibited decreased expression after additional therapy with AMSA and high-dose araC.
Treatment outcome in 36 patients treated with chemotherapy including MDR-related drugs is presented in Table  4 . CR was obtained in only 29% of patients expressing 2 U or more of mdrl (groups +/-, +, and + +), whereas 67% of patients negative formdrl expression achieved CR (P = .03). This difference is significant, even if the patients who died in aplasia are excluded from the analysis (33% v 73%, P = .04). No correlation was found between remission duration and mdrl expression.
In 22 AML patients, in vitro drug sensitivity of leukemic clonogenic cells was determined and compared with the mdrl RNA expression measured on the same sample. All 11 cases with in vitro drug resistance exhibited detectable mdrl expression, while 5 of 11 cases with CFU-L sensitivity to MDR-related drugs did not express increased levels of mdrl expression ( Table 5 ). The correlation between lack of mdrl expression and in vitro sensitivity to several MDRrelated drugs was statistically significant (P = .03).
DISCUSSION
The most important result of our study is the significant inverse association of mdrl expression and the achievement of a CR in adult patients with acute leukemias. The CR rate among patients with low mdrl expression was more than twofold higher than in those with increased mdrl expression, 67% CR versus 29% ( Table 4) . The low overall CR rate of 46% is not surprising considering the prevalence of adverse prognostic factors in this group of patients, with an average age of 45 years and a mean peripheral WBC count
The proportion of cases with increased mdrl mRNA expression is higher in our series than in some other^.^^^^"^'^
The variations between studies may be partly explained by the use of different positive control cell lines and the number of units arbitrarily assigned to these controls. Patient selection might also contribute to differing results. An incidence of increased mdrl mRNA expression similar to our findings has been reported recently for both ALLM and AML.35,36 It is unlikely that mdr2 expression affected our results because it is not selectively expressed in most normal tissues and human tumor cell lines. 37 We did not find a significant difference in the level or distribution of mdrl expression among leukemias before or after therapy, perhaps because there were only 10 samples analyzed after chemotherapy. However, there was a suggestion that high expression may be selected by therapy, with of 115 x 1 0~1~. 50% of patients (5 of 10) exhibiting 10 U or more of expression after treatment, while only 19% of untreated patients expressed such high levels (P = .06). Three of 10 patients who were clinically resistant to MDR drugs did not exhibit mdrl expression, implying that other mechanisms of drug resistance were present ( Table 2) . Recently, high expression of mdrl has been reported in three of four patients with blast crisis of chronic myelogenous leukemia, and may contribute to the poor response of these patients to ~hemotherapy.~~ Although only 19% of leukemias from untreated patients expressed very high levels of mdrl, an additional 19% expressed moderate levels of 5 to 9 U (+), and only 32% of patients were completely negative for mdrl expression. A low but detectable level of expression might be partly explained by the expansion of a subset of immature normal myeloid cells which express mdrl RNA.'9 These positive cells were not detected by RNA slot blotting of normal bone marrow,8 but were demonstrated by in situ RNA hybridization, which can detect mdrl gene expression in a subset of the normal marrow population, and by the polymerase chain reaction. 39 We are continuing to assess the optimal method for detecting mdrl expression in clinical specimens.
No significant correlations were found between the levels of mdrl expression and known adverse prognostic factors in acute leukemia, such as secondary leukemia, patient age, or high WBC count. The remission duration in patients with mdr (+) and mdr (-) leukemic cells did not differ statistically. Any such differences in remission duration might be reduced by the use of consolidation therapy with high-dose araC.
The fact that 29% of patients with detectable mdrl expression attained a CR can be explained in part by the fact that these patients were also treated with non-MDR drugs such as araC, Pdn, and cyclophosphamide. araC For personal use only. on November 15, 2017. by guest www.bloodjournal.org From alone is known to produce a 30% CR rate in untreated AML patient^,^' and Pdn yields a similar result in Moreover, the level of mdrl expression associated with clinical resistance is not known. It is possible that leukemic cells with moderately elevated levels of mdrl expression may still be sensitive to high doses of MDR drugs in vivo. This possibility is supported by the data in Table 5 , part B, showing that some leukemias that expressed mdrl retained sensitivity to MDR-type drugs.
We found a significant correlation between mdrl expression and in vitro sensitivity of clonogenic leukemic cells to Dnr and other MDR-related drugs (Table 5) . A correlation between mdrl expression and Dnr sensitivity by clonogenic assay was also described by Salmon et aI4' in myeloma, lymphoma, and breast cancer. In our study, all five cases with low mdrl expression exhibited sensitivity to Dnr. However, 40% of the specimens expressing greater than 1 U of mdrl also retained sensitivity to Dnr. This finding suggests that factors in addition to mdrl expression are involved in determining cellular sensitivity to MDR-related drugs. A leukemia specimen might also be positive for mdrl expression despite lack of such expression by clonogenic cells, which represent less than 1% of the leukemic population.
Our study provides further evidence that mdrl gene expression may be an important mechanism of drug resistance in human leukemias. Further prospective studies that confirm the prognostic significance of such expression should lead to strategies to overcome or circumvent MDR in patients. Such strategies may include modulation of the function of P-glyc~protein'~ and the use or development of non-cross-resistant drugs with activity in leukemia^.^^
